Found 108 clinical trials
A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide Bortezomib and Dexamethasone (CyBorD) for NDMM NTE
This is a phase 2A multi-centre, open label, pilot study of pembrolizumab added to the standard first-line therapy of cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed
- 0 views
- 31 Jul, 2021
- 4 locations
Phase I Trial of the Combination of Bortezomib and Clofarabine in Adults With Refractory Solid Tumors, Lymphomas, or Myelodysplastic Syndromes
own to treat some blood cell cancers. Objectives To test the safety and efficacy of the drug combination of bortezomib and clofarabine.
- 25 views
- 23 Sep, 2022
- 1 location
VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma
The phase 2 study evaluated the efficacy and safety of bortezomib in combination with lenalidomide as maintenance therapy in high risk newly diagnosed multiple myeloma patients who receive
- 0 views
- 26 Jan, 2021
- 1 location
Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma
This trial studies how well cryocompression therapy works in reducing bortezomib-induced peripheral neuropathy in patients with multiple myeloma. Peripheral neuropathy (nerve pain or tingling in
- 2 views
- 21 Apr, 2022
- 1 location
Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib (IPoD-790)
Adult patients with a confirmed diagnosis of symptomatic and relapsed and/or refractory MM, after receiving bortezomib, lenalidomide and daratumumab during first and second lines, will be
- 102 views
- 24 Jul, 2022
- 7 locations
High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT) Study
a standard of care conditioning regimen. Subjects will receive investigational PTCy, investigational bortezomib and investigational abatacept as GvHD prophylaxis.
- 0 views
- 25 Apr, 2022
- 1 location
DARA RVD For High Risk SMM
The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating
- 0 views
- 30 Oct, 2021
- 2 locations
Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure
daratumumab, bortezomib, dexamethasone, and thalidomide or lenalidomide. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib is a drug that
- 5 views
- 30 Jun, 2022
- 1 location
Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis
regimens between bortezomib-thalidomide-dexamethasone (BTD) and bortezomib-cyclophosphamide-dexamethasone (BCD) in the treatment of AL amyloidosis, so as to provide more clinical evidence for the standard
- 0 views
- 26 Jan, 2021
- 1 location
A Study of Selinexor Plus Low-dose Dexamethasone in Participants With Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone in Participants With Triple-class Refractory Multiple Myeloma
or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.
- 0 views
- 22 Apr, 2022
- 15 locations